Early phase clinical trials: Communicating the uncertainties of 'magnitude of benefit' and 'likelihood of benefit'

Clinical Trials

Volumn 5, Issue 6, 2008, Pages 627-629

  Kass, Nancy E ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHICS; HUMAN; INTERPERSONAL COMMUNICATION; NOTE; PATIENT EDUCATION; PHASE 1 CLINICAL TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME; UNCERTAINTY;

CLINICAL TRIALS, PHASE I AS TOPIC; DISCLOSURE; HUMANS; PATIENT EDUCATION AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME; UNCERTAINTY;

EID: 61449442413     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774508098681     Document Type: Note

References (8)

1. Siminoff LA, Fetting JH. Effects of outcome framing on treatment decisions in the real world: impact of framing on adjuvant breast cancer decisions. Med Decis Making 1989; 9: 262-71.
2. Featherstone K, Donovan JL. "Why don't they just tell me straight, why allocate it?" The struggle to make sense of participating in a randomised controlled trial. Soc Sci Med 2002; 55: 709-19.
3. Flory J, Emanuel E. Interventions to improve research participants' understanding in informed consent for research. JAMA 2004; 292(13): 1593-601.
4. Wadey V, Frank C. The effectiveness of patient verbalization on informed consent. Can J Surg 1997; 40(2): 124-28.
5. Kass N, Sugarman J, Taylor H, Fogarty L, Goodman SN, Goodwin-Landher A, et al. Purpose and benefits of early phase cancer trials: What do oncologists say? What do patients hear? JERHRE 2008 September 2008:57-68.
6. von Hoff DD, Turner J. Response rates, duration of response, and dose response effect in Phase I studies in antineoplastics. Invest New Drugs 1997; 9: 115-22.
7. Arkenau H, Olmos D, Ang JE et al. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer 2008; 98: 1029-33.
8. Horstmann E, McCabe M, Grochow L et al. Risks and benefits of phase I oncology trials, 1991 through 2002. NEJM 2005; 352(9): 895-904.